Vladonix
Thymus peptide complex
Vladonix (Thymus peptide complex) is a longevity & bioregulators research compound. Thymus-derived peptide complex — supports immune regulation and T-cell function, aimed at age-related immune decline.
Vladonix quick facts
| Reported research dose (Injectable) | 2mg-5mg (per course) |
| Route | Subq |
| Frequency | 1x Daily · Daily (course) |
| Half-life | ~15-30 min |
| Forms | Injectable, Oral |
| Evidence level | Russian studies; limited |
| Other forms available | Oral — dosed differently |
Immune/thymus bioregulator complex — course-based. The thymus/immune complex of the set. Course pattern: roughly 10 days on, then off, once or twice a year. To know whether it did anything, CBC with differential before and after a season. Run it as an experiment you measure, not a protocol you trust.
How Vladonix works
Thymus-derived peptide complex — supports immune regulation and T-cell function, aimed at age-related immune decline.
Proposed benefits
Researched for mitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.
Where to get Vladonix
Bacteriostatic water is the diluent — sterile water with 0.9% benzyl alcohol, which is what lets a vial be drawn from more than once. It does not come with the vial, and unlike the compound it is bought again every time.
Need bacteriostatic water? Get it at AminoWell USA (my company) → Code CAMERON.
The evidence for Vladonix
Graded by what exists behind each claim.
Human clinical evidence
- The human record is Soviet and post-Soviet clinical work — real patients and real endpoints, published in Russian and rarely replicated to Western standards.
📊 Correlative data
- Sold as an oral thymus peptide complex for age-related immune decline. It occupies the same space as Thymalin without Thymalin's mortality follow-up behind it — the two are not interchangeable in evidence, only in intent.
🧪 Theoretical / extrapolated
- A thymus-derived peptide complex targeting T-cell regulation. Thymic involution is real and immunosenescence is a well-described phenomenon, so the target is sound even where the agent is unproven.
- Two things at once: the mechanism is a real, testable hypothesis with published cell-level work behind it, and essentially all of that work is one group's, unreplicated at scale.
- Oral delivery is the specific weak point here — an undefined peptide mixture taken by mouth has to survive digestion intact, and nobody has demonstrated that it does.
How to read the Soviet clinical series → · The Khavinson series, in full →
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Vladonix actually does
Vladonix is not a peptide. It is a peptide complex, and the difference decides what can honestly be said about it. A defined peptide has a sequence, so it has a formula, a mass, an isoelectric point and a computable charge at blood pH — every one of which can be checked against a vial. A complex is what is left after animal thymus tissue is extracted and fractionated by size. It has a molecular weight range rather than a molecular weight, and its composition is standardized by total protein content rather than by what the protein is.
What that means in practice is worth stating without euphemism. A certificate of analysis for a preparation like this can establish sterility, endotoxin level, total peptide content and the absence of named contaminants. It cannot establish identity, because there is no structure to match against. Two lots with identical certificates can be different mixtures, and no test in routine use tells them apart. Every number on this page that describes a defined peptide — 319.28 Da for Chonluten, 489.50 Da for Cardiogen — has no counterpart here, and that absence is the single most important fact about the product.
The proposed mechanism, and where it runs out. The class argument is that short peptides from an organ act preferentially on that organ by reaching chromatin and shifting transcription Khavinson 2021. For a complex, that argument has a gap at the first step: the named routes into a cell are the proton-coupled oligopeptide transporters PEPT1 and PEPT2 and the amino-acid transporters LAT1 and LAT2, whose described substrate range is di- and tripeptides Khavinson 2022. Di- and tri- means 2 and 3 residues. A mixture of unstated chain lengths is neither, so the one named delivery route cannot be claimed for it — not because the mixture fails the test, but because nobody knows what is in the mixture to test.
The target, at least, is real. Thymic involution is not a marketing invention. The thymus shrinks with age, output of new naive T cells falls, the naive-to-memory ratio shifts and the CD4/CD8 ratio drifts. That decline is measurable, it is clinically consequential, and it is a legitimate thing to want to reverse. The question this page has to answer is whether this product touches it, and the answer is that nobody has looked.
Cell, rodent, human — and where it stops
The evidence people buy this on belongs to a different product. Thymalin is the thymus preparation with a human record: the 266-subject elderly series in which thymus and pineal preparations were injected over 6 to 8 years Khavinson 2003, and the more recent work reporting effects on immune status in older patients with severe COVID-19 (Kuznik and colleagues, Advances in Gerontology, 2021, in the sources below). Vladonix is sold into the same space. The two are not interchangeable in evidence, only in intent, and no published work compares them — not by composition, not by potency, not by endpoint.
What the Thymalin literature actually attributes the effect to. Reviews from the originating group name 3 short peptides as the active constituents: the dipeptide Lys-Glu, the dipeptide Glu-Trp, and the tripeptide Glu-Asp-Pro. That matters here in a way it does not on other pages: if the activity of a thymus preparation is carried by named short peptides, then a thymus preparation that does not state its content of those peptides is selling an unknown quantity of the active ingredient. No vendor of this product publishes that assay.
In animals: nothing under this trade name. In cells: nothing under this trade name either — but the preparation next to it on the shelf does have a cell paper, and it is worth knowing what it found. A 2022 study in International Journal of Molecular Sciences put 5 named preparations from this family, Thymalin among them, onto THP-1, a human monocytic leukemia line differentiated into macrophages Avolio 2022. All 5 raised tyrosine phosphorylation of mitogen-activated cytoplasmic kinases and all 5 suppressed TNF and interleukin-6 released in response to bacterial lipopolysaccharide, and peptide-treated monocytes adhered less to activated endothelial cells. Two things follow. The mechanism on offer is anti-inflammatory action on macrophages, which is a different and more specific claim than restoring thymic output. And the Saint Petersburg institute that originated these peptides is on the author list, so it is a collaboration rather than independent replication. The work is Thymalin's; this product borrowed the shelf, not the data.
The obstacles, in order of how much they cost you. (1) Identity. Without a composition you cannot compute a dose, predict a marker or compare 2 vendors. (2) Route. The oral form faces gastric acid, pancreatic proteases, brush-border peptidases and then a transporter whose stated range excludes anything longer than 3 residues Khavinson 2022; the injectable form skips all of that and has no published pharmacokinetics either. (3) Borrowed evidence. Every human result cited for this product was generated with a different preparation. (4) The outside view: the independent systematic review of this family pooled 24 randomized trials over 2,245 participants, judged risk of bias moderate to high and certainty of evidence low to very low, and covered cognitive endpoints rather than immune ones Alsulaimani 2021.
What would have to be true, and how you would know it was not
Three predictions, and the second is the one that would settle whether anything in this category works at all.
1. A CBC with differential is the floor, and it is a weak test. Total lymphocyte count is what people actually measure, it is on every CBC, and it moves with infection, stress, cortisol and time of day far more than it would plausibly move with a peptide course. Draw it before and after, expect no change, and treat any change as a question rather than an answer. This site retests a CBC at 3 and 6 months on an ongoing protocol, which is the right cadence here too.
2. The real test is a lymphocyte subset panel, and the prediction is specific. If a thymus preparation restores thymic output, the naive CD4 fraction should rise and the CD4/CD8 ratio should move toward the young pattern. Those are ordinary flow cytometry measurements, orderable, and they are the only readouts that distinguish new T cells from redistributed old ones. A total lymphocyte count cannot make that distinction. Nobody has run a subset panel before and after a course of this product.
3. The prediction that cuts against it: hs-CRP and ESR should not fall, and a course should not reduce how often you get sick in the first season. There is no mechanism here that predicts an anti-inflammatory effect in a healthy adult, and infection frequency over 1 winter in 1 person is noise. If somebody reports fewer colds after a course, the honest reading is that colds are seasonal, self-limited and highly variable, and that a single uncontrolled observation cannot separate the peptide from the year.
What nobody has tested yet
Four experiments, and the first one has been available for 20 years.
1. Nobody has counted T-cell receptor excision circles. TRECs are DNA by-products of T-cell receptor rearrangement that survive only in cells that recently left the thymus, which makes the assay a direct measure of thymic output rather than a proxy for it. It is a standard clinical laboratory test, it is used in newborn screening, and it has never been measured before and after a course of any product in this family, including Thymalin. The entire immune-rejuvenation claim of this category rests on a number nobody has collected.
2. Nobody has published a proteomic profile of a lot. Liquid chromatography with tandem mass spectrometry on a single capsule would list what is in it. That would answer the identity question permanently and would also show whether the 3 short peptides the Thymalin literature names as active are present at all, and in what proportion.
3. Nobody has compared the oral and the injectable form of the same extract. This product is sold both ways. If the oral form works, the transporter objection is wrong and that is a major finding; if only the injectable works, the oral product should not be sold. 1 trial with 2 arms and a lymphocyte subset endpoint would answer it, and 0 have been run.
4. Nobody has compared it with Thymalin. Same tissue, same claimed mechanism, wildly different evidence bases, sold side by side. A head-to-head on any immune endpoint would tell a buyer which one to choose, which is presumably why no seller has funded it.
Vladonix — its own safety story, not its class's
Three things specific to a thymus extract, none of which the class block covers.
Bovine-derived tissue extracts carry a source question that synthetic peptides do not. A synthetic tripeptide is built from reagents. An organ extract is made from an animal, which raises questions about herd sourcing, viral inactivation and residual protein that only the manufacturer can answer, and which no certificate of sterility addresses. This is not a claim that harm has occurred — no such report exists — it is a category of risk that is absent for the defined peptides in the same catalog and present here.
Immune-directed products and immune-suppressed people are a bad combination to guess about. Anyone on transplant medication, on a biologic for autoimmune disease, or on cancer immunotherapy is having their immune system held at a deliberate level. Adding a preparation whose stated purpose is to change immune status, with 0 published interaction studies and no known composition, is the one situation on this page that warrants a flat refusal rather than monitoring.
A falling lymphocyte count is a finding, not a side effect. If a CBC drawn during a course shows a lymphocyte count outside the reference range, the differential diagnosis includes infection, medication effect and hematological disease — and the correct response is to investigate the person rather than to blame or credit the capsule. There are 0 published adverse events for this product, and with 0 human trials there was never a setting in which one could have been recorded.
Sources read for this page
- Avolio F, et al. (co-authors include Khavinson VKh). Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line. International Journal of Molecular Sciences 2022;23(7):3607 · PMID 35408963
- Kuznik B, Khavinson V, Shapovalov K, Linkova N, Lukyanov S, Smolyakov Yu, Tereshkov P, Shapovalov Yu, Konnov V, Tsybikov N. Peptide Drug Thymalin Regulates Immune Status in Severe COVID-19 Older Patients. Advances in Gerontology 2021;11(4):368–376
- Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinology Letters 2003;24(3-4):233–240 · PMID 14523363
- Khavinson VKh, Linkova NS, Chalisova NI, Ivko OM. The Use of Thymalin for Immunocorrection and Molecular Aspects of Biological Activity. Biology Bulletin Reviews 2021;11(4):377–382
- Khavinson V, Linkova N, Kozhevnikova E, Dyatlova A, Petukhov M. Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers. International Journal of Molecular Sciences 2022;23(14):7733 · PMID 35887081
- Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules 2021;26(22):7053 · PMID 34834147
- Alsulaimani RA, Quinn TJ (independent — not the Khavinson group). The efficacy and safety of animal-derived nootropics in cognitive disorders: Systematic review and meta-analysis. Cerebral Circulation – Cognition and Behavior 2021;2:100012 · PMID 36324709
Vladonix — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- These are short peptide fragments of organ extracts, and the honest starting point is that the mechanism itself is not established in a way that lets anyone predict harm precisely. The proposal is gene-regulatory — short peptides binding DNA and modulating transcription in a tissue-specific way. If that is what they do, the theoretical concern is influencing transcription in tissue you were not aiming at.
- In practice the doses are tiny, the peptides are short, and they are degraded quickly — which is also the argument that they may do very little at all. Those two possibilities are the same uncertainty viewed from opposite ends, and you should hold both.
What has actually been reported
- Decades of Russian clinical use with a strikingly clean tolerability record — injection-site reactions and little else reported.
- That record comes almost entirely from one research school, is largely unreplicated outside it, and safety data from a group with an interest in the outcome is worth less than the same data from a skeptic. This is not an accusation; it is how evidence weighting works.
How to reduce the risk
Same mechanism as the prediction.
- Follow the course printed on the label rather than running continuously. These are the one class in the Vault where a duration is STATED rather than inferred, and it is typically 10–20 days repeated a few times a year. Read the box.
- Run one at a time. They are cheap and it is tempting to stack six. If something changes, a stack of six tells you nothing about which one did it — and given the evidence base, attribution is the entire value of your own experiment.
- Decide your endpoint before you start, and make it a marker or a measurable symptom rather than a feeling. With a compound class this under-evidenced, an unfalsifiable endpoint means you will conclude it worked no matter what happened.
- Buy from a source that publishes third-party testing. Where the molecule itself is uncertain, identity and purity are the only variables you can actually control.
What it does to your bloodwork
A fact about the assay.
- Test the ORGAN, not the peptide. A thymic peptide is judged on immune markers, a pineal one on sleep and IGF-1, a vascular one on lipids and inflammatory markers. There is no assay for the compound itself.
Don't run this if
- Pregnancy — not because of a specific finding, but because nobody has studied it and the mechanism claim is transcriptional.
- Active malignancy, on the same reasoning as any tissue-growth signal: unproven, mechanistically arguable, and not worth finding out.
The honest unknown
- Essentially everything a skeptic would want: independent replication, pharmacokinetics, and whether the oral forms survive digestion at all. Unproven is not the same as ineffective — but here it is a large unproven.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Vladonix — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Vladonix moves on your bloodwork
Expected direction, not a measured one.
- Comprehensive Metabolic Panel (CMP) — ◆ worth watching
These are short peptide fragments given in microgram amounts and there is no mechanism predicting a specific marker shift. Listing markers here would be padding.
What to do: Test the organ system the bioregulator is aimed at, not a generic panel — that is the only measurement that would tell you anything.
The evidence base here is almost entirely one research group's, largely in Russian, and rarely replicated independently. That is the single most important thing to know before running a course, and it is more useful than any interaction list.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Needle gauge and injection site
- How the forms differ in dose
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Vladonix in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Vladonix
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Chronic low-grade inflammation is the process most of these target |
| ApoB (Apolipoprotein B) | Counts the particles that actually cause plaque, unlike LDL-C |
| HbA1c (Hemoglobin A1c) | Glycation, which is the other half of the ageing story |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney — the two organs that clear everything you take |
| Complete Blood Count (CBC) with Differential | The cheapest broad screen there is |
The Longevity Baseline panel covers these in one order — 13 markers, $219.10 with the discount applied.
Check results you already have → · All 103 markers A–Z
Vladonix — frequently asked questions
What is Vladonix?
Vladonix (Thymus peptide complex) is a longevity & bioregulators research compound. Thymus-derived peptide complex — supports immune regulation and T-cell function, aimed at age-related immune decline.
Is the full Vladonix protocol on this page?
The reported research dose is on this page, along with how Vladonix works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of Vladonix?
Vladonix has an approximate half-life of ~15-30 min, which is part of what determines how often it's dosed.
What forms does Vladonix come in?
Vladonix is available as: Injectable, Oral.
What's the evidence behind Vladonix?
Current evidence level: Russian studies; limited. Vladonix is offered for research purposes only and is not an approved medicine.
Vladonix inside a finished plan
One arm of 1 Protocol Blueprint, free to read in full.
What Vladonix is used for
Vladonix appears under 2 goals in the goal router.
Related Longevity & Bioregulators compounds
Where this goes next
Vladonix is the immune arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.